Related Experiment Videos
Impact of cytomegalovirus infection on organ transplant recipients
1Infectious Disease Unit, Massachusetts General Hospital, Boston 02114.
Abstract:
Cytomegalovirus (CMV) is the single most important infectious agent affecting recipients of organ transplants, with at least two-thirds of these patients having CMV infection 1-4 months after transplantation. Latently infected allografts are the major exogenous source of CMV infection in transplant recipients, although leukocyte-containing blood products can also transmit the virus. Three patterns of CMV infection are recognized: primary infection, reactivation infection, and superinfection. Primary infection has the greatest clinical impact. The clinical effects of CMV infection include infectious disease syndromes such as pneumonia and chorioretinitis; an immunosuppressed state that predisposes to potentially lethal opportunistic infection; and the initiation of a process that can result in allograft injury. Progress has been made in controlling CMV infection; hyperimmune anti-CMV globulin and certain antiviral drugs appear promising for prophylaxis, and the combination of hyperimmunoglobulin and ganciclovir appears promising for therapy.
Insights
Cytomegalovirus (CMV) infection significantly impacts organ transplant recipients, often originating from the transplanted organ. Early diagnosis and treatment are crucial for managing this common post-transplant complication.
Area of Science:
- Infectious Diseases
- Transplantation Immunology
- Virology
Background:
- Cytomegalovirus (CMV) is a primary infectious complication in organ transplant recipients, affecting at least two-thirds of patients within 1-4 months post-transplant.
- The major source of CMV infection is latently infected allografts, with leukocyte-containing blood products also identified as a transmission route.
- CMV infection presents in three patterns: primary, reactivation, and superinfection, with primary infection carrying the most significant clinical burden.
Purpose of the Study:
- To review the epidemiology, clinical impact, and management strategies for Cytomegalovirus (CMV) infection in organ transplant recipients.
- To highlight the significance of CMV as an infectious agent in the context of organ transplantation.
- To discuss current and emerging therapeutic approaches for CMV infection.
Main Methods:
- Literature review of Cytomegalovirus (CMV) infection in organ transplant recipients.
- Analysis of epidemiological data and clinical manifestations of CMV infection.
- Evaluation of prophylactic and therapeutic interventions for CMV.
Main Results:
- CMV infection is a leading cause of morbidity and mortality in transplant recipients, manifesting as pneumonia, chorioretinitis, and allograft injury.
- Primary CMV infection has the most severe clinical consequences, including increased susceptibility to opportunistic infections.
- Hyperimmune anti-CMV globulin and antiviral drugs show promise for prophylaxis and therapy, with combined hyperimmunoglobulin and ganciclovir being a potentially effective treatment.
Conclusions:
- Cytomegalovirus (CMV) infection poses a significant threat to organ transplant recipients, impacting graft survival and patient health.
- Effective prophylaxis and therapeutic strategies, including antiviral agents and hyperimmune globulin, are essential for managing CMV.
- Continued research and clinical vigilance are necessary to mitigate the adverse effects of CMV in this vulnerable patient population.